President & Ceo at RXi Pharmaceuticals Corp (NASDAQ:RXII) Geert Cauwenbergh has acquired 2,000 shares of common stock, $0.0001 par value, at an average price of $2.9 per share. Over the course of 2014, Mr. Cauwenbergh is the only insider to have procured stock at this $40.12 million Market Cap biotechnology company. During 2013, Mr. Cauwenbergh acquired 14,767 shares at prices ranging from $2.9 to $4.8 per share. Following the reported transaction, the President & Ceo owns 23,100 shares at the company.
Other insiders to have procured stock during 2013 are Directors Robert Bitterman, who acquired 1,500 shares, at average price of $ 4, and Curtis Lockshin, who procured 1,000 shares, at a price of $3.7 per share. Other transactions RXi Pharmaceuticals Corp (NASDAQ:RXII) insider have been registered as well. Large shareholder Galena Biopharma, Inc. sold more than 1 million shares during 2013, at prices ranging from $0.19 to $0.21 per share.
Moreover, none of the major hedge funds that we track hold long positions in this stock.